Prolonged suppression of human immunodeficiency virus type 1 (HIV-1) viremia in persons with advanced disease results in enhancement of CD4 T cell reactivity to microbial antigens but not to HIV-1 antigens

Journal of Infectious Diseases

Volumn 179, Issue 2, 1999, Pages 329-336

  Rinaldo Jr , Charles R ^a   Liebmann, James M ^b   Huang, Xiao Li ^b   Fan, Zheng ^b   Al Shboul, Qasim ^b   McMahon, Deborah K ^b   Day, Richard D ^b   Riddler, Sharon A ^b   Mellors, John W ^b  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; INDINAVIR; INTERLEUKIN 10; LAMIVUDINE; RANTES; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; FEMALE; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSTIMULATION; LYMPHOCYTE PROLIFERATION; MALE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VIREMIA; VIRUS LOAD; VIRUS REPLICATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; ANTIGENS, BACTERIAL; CD4-POSITIVE T-LYMPHOCYTES; CELL DIVISION; CHEMOKINES; CYTOKINES; DOUBLE-BLIND METHOD; FEMALE; HIV ANTIGENS; HIV-1; HUMANS; INDINAVIR; LAMIVUDINE; MALE; MITOGENS; RNA, VIRAL; VIREMIA; ZIDOVUDINE;

EID: 0033024591     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314599     Document Type: Article

References (30)

1. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-2.
2. Gulick RM, Mellors JW, Havlir D, et al. Simultaneous vs. sequential initiation of therapy with indinavir, zidovudine, and lamivudine in for HIV-1 infection. 100 weeks of follow-up. JAMA 1998;280:35-41.
3. Levy JA. HIV and the pathogenesis of AIDS. 2nd ed. Washington, DC: American Society for Microbiology Press, 1997:588.
4. Lane HC, Depper JM, Greene WC, Whalen G, Waldmann TA, Fauci AS. Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome. Evidence for a selective defect in soluble antigen recognition. N Engl J Med 1985;313:79-84.
5. Wahren B, Morfeldt-Månsson G, Biberfeld L, et al. Characteristics of the specific cell-mediated immune response in human immunodeficiency virus infection. J Virol 1987;61:2017-23.
6. Hofmann B, Lindhardt BO, Gerstoft J, et al. Lymphocyte transformation response to pokeweed mitogen as a predictive marker for development of AIDS and AIDS-related symptoms in homosexual men with HIV antibodies. Br Med J 1987;295:293-6.
7. Miedema F, Petit AJC, Terpstra FG, et al. Immunological abnormalities in human immunodeficiency virus (HIV) infected asymptomatic homosexual men. HIV affects the immune system before CD4' T helper cell depletion occurs. J Clin Invest 1988;82:1908-14.
8. Clerici M, Stocks NI, Zajac RA, et al. Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients. Independence of CD4' T cell numbers and clinical staging. J Clin Invest 1989;84:1892-9.
9. Dawson JD, Lagakos SW. Analyzing laboratory markers change in AIDS clinical trials. J Acquir Immmune Defic Syndr 1991;4:667-76.
10. Dawson JD. Comparing treatment groups on the basis of slopes, areas under the curve, and other summary measures. Drug Information J 1994;28:723-32.
11. Frisonn L, Pocock SJ. Repeated measures in clinical trials: analysis using mean summary statistics and its implications for design. Stat Med 1992;11:1685-704.
12. Laird NM, Wang F. Estimating rates of change in randomized clinical trials. Control Clin Trials 1990;11:405-19.
13. Autran B, Carcelain F, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4' T cell homeostasis and function in advanced HIV disease. Science 1997;277:112-6.
14. Li TS, Tubiana R, Katlama C, Calvez V, Ait Mohand H, Autran B. Longlasting recovery in CD4' T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 1998;351:1682-6.
15. Young HA, Hardy KJ. Role of interferon-γ in immune cell regulation. J Leukoc Biol 1995;58:373-81.
16. Taub DD, Ortaldo JR, Turcovski-Corrales SM, Key ML, Longo DL, Murphy WJ. β chemokines costimulate lymphocyte cytolysis, proliferation, and lymphokine production. J Leukoc Biol 1996;59:81-9.
17. +cells. Science 1995;270:1811-5.
18. Mackall CL, Fleischer TA, Brown MR, et al. Age, thymopoiesis, and CD4' T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med 1995;332:143-9.
19. Mackall CL, Fleischer TA, Brown MR, et al. Distinctions between CD8' and CD4' T-cell regenerative pathways result in prolonged T-cell subset imbalance after intensive chemotherapy. Blood 1997;89:3700-7.
20. Mackall CL, Hakim FT, Gress RE. T-cell regeneration: all repertoires are not created equal. Immunol Today 1997;18:245-51.
21. Hakim FT, Cepeda R, Kaimai S, et al. Constraints on CD4 recovery postchemotherapy in adults: thymic insufficiency and apoptotic decline of expanded peripheral CD4 cells. Blood 1997;90:3789-98.
22. Rosenberg ES, Billingsley JM, Caliendo AM, et al. Vigorous HIV-1-specific CD4' T cell responses associated with control of viremia. Science 1997;278:1447-50.
23. Wong JK, Hazareh M, Gunthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997;278:1291-5.
24. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997;278:1295-300.
25. Chun TW, Stuyver L, Mizell S, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 1997;94:13193-7.
26. Connors M, Kovacs JA, Krevat S, et al. HIV infection induces changes in CD4' T-cell phenotype and depletions within the CD4' T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nature Med 1997;3:533-40.
27. Riddell SR, Greenberg PD. Principles for adoptive T cell therapy of human viral diseases. Annu Rev Immunol 1995;13:545-86.
28. Dupuis M, Peshwa MV, Benike C, et al. Allogeneic dendritic cell induction of HIV-specific cytotoxic T lymphocyte responses from T cells of HIV type 1 infected and uninfected individuals. AIDS Res Hum Retroviruses 1997;13:33-9.
29. Knight SC, Patterson S. Bone marrow-derived dendritic cells, infection with human immunodeficiency virus, and immunopathology. Annu Rev Immunol 1997;15:593-615.
30. Fan Z, Huang X, Zheng L, et al. Cultured blood dendritic cells retain HIV-1 antigen-presenting capacity for memory CTL during progressive HIV-1 infection. J Immunol 1997;159:4973-82.